These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 28947922)

  • 21. Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance.
    Heise M; Lautem A; Knapstein J; Schattenberg JM; Hoppe-Lotichius M; Foltys D; Weiler N; Zimmermann A; Schad A; Gründemann D; Otto G; Galle PR; Schuchmann M; Zimmermann T
    BMC Cancer; 2012 Mar; 12():109. PubMed ID: 22439694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of the genetic variants of organic cation transporters 1 and 3 on the pharmacokinetics of metformin in Jordanians.
    Hakooz N; Jarrar YB; Zihlif M; Imraish A; Hamed S; Arafat T
    Drug Metab Pers Ther; 2017 Sep; 32(3):157-162. PubMed ID: 28862982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted disruption of organic cation transporter 3 attenuates the pharmacologic response to metformin.
    Chen EC; Liang X; Yee SW; Geier EG; Stocker SL; Chen L; Giacomini KM
    Mol Pharmacol; 2015 Jul; 88(1):75-83. PubMed ID: 25920679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis.
    Clarke JD; Dzierlenga AL; Nelson NR; Li H; Werts S; Goedken MJ; Cherrington NJ
    Diabetes; 2015 Sep; 64(9):3305-13. PubMed ID: 26016715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes.
    Tkáč I; Klimčáková L; Javorský M; Fabianová M; Schroner Z; Hermanová H; Babjaková E; Tkáčová R
    Diabetes Obes Metab; 2013 Feb; 15(2):189-91. PubMed ID: 22882994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic and Epigenetic Regulation of Organic Cation Transporters.
    Kölz C; Schaeffeler E; Schwab M; Nies AT
    Handb Exp Pharmacol; 2021; 266():81-100. PubMed ID: 33674913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.
    Tzvetkov MV; Vormfelde SV; Balen D; Meineke I; Schmidt T; Sehrt D; Sabolić I; Koepsell H; Brockmöller J
    Clin Pharmacol Ther; 2009 Sep; 86(3):299-306. PubMed ID: 19536068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of genetic factors and kidney and liver function in glycemic control in type 2 diabetes patients on long-term metformin and sulphonylurea cotreatment.
    Klen J; Goričar K; Janež A; Dolžan V
    Biomed Res Int; 2014; 2014():934729. PubMed ID: 25025077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of
    Chen P; Cao Y; Chen S; Liu Z; Chen S; Guo Y
    Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin.
    Shikata E; Yamamoto R; Takane H; Shigemasa C; Ikeda T; Otsubo K; Ieiri I
    J Hum Genet; 2007; 52(2):117-122. PubMed ID: 17111267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The variant organic cation transporter 2 (OCT2)-T201M contribute to changes in insulin resistance in patients with type 2 diabetes treated with metformin.
    Kashi Z; Masoumi P; Mahrooz A; Hashemi-Soteh MB; Bahar A; Alizadeh A
    Diabetes Res Clin Pract; 2015 Apr; 108(1):78-83. PubMed ID: 25662675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of the SLC22A1, SLC22A2, and SLC22A3 genes encoding organic cation transporters with diabetic nephropathy and hypertension.
    Sallinen R; Kaunisto MA; Forsblom C; Thomas M; Fagerudd J; Pettersson-Fernholm K; Groop PH; Wessman M;
    Ann Med; 2010 May; 42(4):296-304. PubMed ID: 20429798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic Alterations in Human Liver From Subjects With Type 2 Diabetes in Parallel With Reduced Folate Levels.
    Nilsson E; Matte A; Perfilyev A; de Mello VD; Käkelä P; Pihlajamäki J; Ling C
    J Clin Endocrinol Metab; 2015 Nov; 100(11):E1491-501. PubMed ID: 26418287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between DNA Methylation in the 5' CpG Island of the
    Tanaka T; Hirota T; Ieiri I
    Mol Pharmacol; 2018 Jan; 93(1):1-7. PubMed ID: 29070695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic and epigenetic regulation of the organic cation transporter 3, SLC22A3.
    Chen L; Hong C; Chen EC; Yee SW; Xu L; Almof EU; Wen C; Fujii K; Johns SJ; Stryke D; Ferrin TE; Simko J; Chen X; Costello JF; Giacomini KM
    Pharmacogenomics J; 2013 Apr; 13(2):110-20. PubMed ID: 22231567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epigenetic effects of metformin: From molecular mechanisms to clinical implications.
    Bridgeman SC; Ellison GC; Melton PE; Newsholme P; Mamotte CDS
    Diabetes Obes Metab; 2018 Jul; 20(7):1553-1562. PubMed ID: 29457866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Organic cation transporter 1 (OCT1) modulates multiple cardiometabolic traits through effects on hepatic thiamine content.
    Liang X; Yee SW; Chien HC; Chen EC; Luo Q; Zou L; Piao M; Mifune A; Chen L; Calvert ME; King S; Norheim F; Abad J; Krauss RM; Giacomini KM
    PLoS Biol; 2018 Apr; 16(4):e2002907. PubMed ID: 29659562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of short chain fatty acid producing bacteria on epigenetic regulation of FFAR3 in type 2 diabetes and obesity.
    Remely M; Aumueller E; Merold C; Dworzak S; Hippe B; Zanner J; Pointner A; Brath H; Haslberger AG
    Gene; 2014 Mar; 537(1):85-92. PubMed ID: 24325907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma.
    Schaeffeler E; Hellerbrand C; Nies AT; Winter S; Kruck S; Hofmann U; van der Kuip H; Zanger UM; Koepsell H; Schwab M
    Genome Med; 2011 Dec; 3(12):82. PubMed ID: 22196450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice.
    Tahara A; Takasu T
    Endocr Res; 2020; 45(2):147-161. PubMed ID: 31955626
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.